Hybutimibe

海博麦布

Report date: 2025/01/22 14:35:53
NME

Base Information

Drug NameHybutimibe
Drug Alias Name海泽麦布Hyzetimibe赛斯美HS-25
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNiemann-Pick C1-like protein 1 inhibitors
TargetsNiemann-Pick C1-like protein 1
Therapy Area/IndicationsHypercholesterolemiaAtherosclerosis
Global Approved IndicationsHypercholesterolemia
Approved Indications in ChinaHypercholesterolemia
Original Approved Country/TerritoryMainland China
Original Approved Date2021/06/25
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesHanhui Pharmaceuticals Company Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdQianfoshan Hospital, Shandong Province
Inactive CompaniesN/A
Active IndicationsHypercholesterolemiaAtherosclerosis
Inactive IndicationsN/A

Other Information

ATC CodeC10AX
Related LinksN/A